Last Updated: November 8, 2026

Details for New Drug Application (NDA): 204150

« Back to Dashboard


NDA 204150 describes DESVENLAFAXINE, which is a drug marketed by Alembic Pharms Ltd, Sun Pharm, Teva Pharms Usa, Actavis Labs Fl, Alembic, Hikma, Lupin, Macleods Pharms, Pharmobedient, Platinum, Rubicon Research, Yichang Humanwell, and Zydus Pharms, and is included in fourteen NDAs. It is available from two suppliers. Additional details are available on the DESVENLAFAXINE profile page.

The generic ingredient in DESVENLAFAXINE is desvenlafaxine succinate. There are three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
Summary for 204150
Tradename:DESVENLAFAXINE
Applicant:Alembic Pharms Ltd
Ingredient:desvenlafaxine
Patents:0
Pharmacology for NDA: 204150
Mechanism of ActionCytochrome P450 2D6 Inhibitors
Norepinephrine Uptake Inhibitors
Serotonin Uptake Inhibitors
Suppliers and Packaging for NDA: 204150
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DESVENLAFAXINE desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204150 NDA Alembic Pharmaceuticals Limited 46708-152 46708-152-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-152-30)
DESVENLAFAXINE desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204150 NDA Alembic Pharmaceuticals Limited 46708-152 46708-152-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (46708-152-90)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength50MG
Approval Date:Mar 4, 2013TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Mar 4, 2013TE:RLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links